Takeda Pharmaceutical Co., Japan’s largest drugmaker, agreed to buy the local unit of Amgen Inc., gaining cancer and arthritis medicines.
The financial terms include an upfront cash payment to Amgen of $200 million, the companies said in a statement Monday.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.